MeMed

MeMed is an Israeli healthtech company that developed a diagnostic test distinguishing between bacterial and viral infections. Its primary product, BriefCase, is a point-of-care device that analyzes blood proteins and delivers a result within minutes, designed to help clinicians decide whether to prescribe antibiotics.

BriefCase measures a combination of blood biomarkers — including TRAIL, IP-10, and CRP — to differentiate between bacterial and viral etiologies of febrile illness. The problem MeMed addresses is antibiotic overuse driven by the clinical difficulty of determining infection origin at the point of care. The primary buyers are healthcare institutions, hospitals, and clinics, with a focus on emergency medicine teams and primary care physicians.

MeMed is headquartered in Haifa. The founders are Israeli, and the company's research was developed in part in collaboration with Israeli academic and medical institutions. Further verified details about the company's Israeli operations are not available in public sources.